secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAPTYSBIO, INC (ANAB)
CIK:        0001370053
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001370053-23-000064
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AnaptysBio Q3 net loss $37.3M ($1.41/sh); imsidolimab Phase 3 GPP hits primary endpoint
--------------------------------------------------------------------------------

- Net loss $37.3M ($1.41/sh) vs $33.5M ($1.18/sh) YoY; R&D spend rose to $30.9M.
- Cash $453.3M at Sep 30, down $130.9M; reaffirms cash runway through year-end 2026.
- Imsidolimab Phase 3 GPP: 53.3% achieved GPPPGA 0/1 vs 13.3% placebo (p=0.0131); out-license planned in 2024.
- Initiated Phase 2b rosnilimab RA trial (420 pts); Phase 2 UC trial starting Q4 2023; top-line mid-2025 and H1 2026.
- Collaboration revenue from Jemperli royalties $3.3M (vs $1.3M) helped offset net loss expansion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1370053/000137005323000064/0001370053-23-000064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1370053/000137005323000064/anab-20231102.htm
  HTML page:      https://secwatch.observer/filing/0001370053-23-000064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer